Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Valo Therapeutics Ltd logo — Reinventing Cancer Immunotherapy

Valo Therapeutics Ltd

Reinventing Cancer Immunotherapy

Founded 2016 Finland Finland 11 employees Total: $39.21M Biotechnology, Health Care +1

General Information

Company Name Valo Therapeutics Ltd
Founded Year 2016
Location Finland Finland
Employees 11
Industries Biotechnology, Health Care, Health and Wellness
Business Model B2B, B2B2C
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Valo Therapeutics Ltd. To contact Valo Therapeutics Ltd, visit valotx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Valo Therapeutics Ltd compare?

A PDF of Valo Therapeutics Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Valo Therapeutics Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Valo Therapeutics Ltd

Valo Therapeutics Ltd, founded in 2016 and headquartered in Finland, is a promising player in the Biotechnology and Health Care sectors. Presenting itself with the slogan "Reinventing Cancer Immunotherapy", ValoTx is at the forefront of developing innovative immunotherapies for cancer and infectious diseases.

The company's approach leverages oncolytic viruses and viral vectors, integrated with disease-specific peptides, to create adaptive and immunogenic therapeutic vaccination platforms. Spun out from the University of Helsinki, the company boasts a team of experts capable of driving its patented technologies through clinical trials and to the market.

The management has a commendable track record of evolving laboratory concepts into publicly listed entities. Recently, ValoTx secured a €19.00M early VC investment on 01 March 2025, backed by investors such as Indaco Venture Partners, CDP Venture Capital SGR, and Fondazione ENEA Tech, reflecting strong investor confidence in its potential.

Business keywords: cancer immunotherapy, oncolytic viruses, viral vectors, therapeutic vaccination, PeptiCRAd platform, PeptiENV, antigen-coated viruses, neoantigen strategies, disease-specific peptides, tumor-specific vaccines, biopharmaceutical development, immunotherapy expertise, adenovirus-based therapies, clinical development, infectious disease treatment

Services & Products

Development of Novel Immunotherapies
Cancer Treatment Platforms
Oncolytic and Non-replicating Vector Technologies

Target Customers

Cancer Patients Healthcare Providers Medical Researchers Pharmaceutical Companies

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC €19.00M 3
Indaco Venture Partners CDP Venture Capital SGR
Indaco Venture Partners, CDP Venture Capital SGR +1
01 Mar 2025
Early VC €11.00M 2
Freeman Company
Freeman Company, Mmj Group Holdings
01 Nov 2021
Seed $1.21M -
01 Feb 2020
Debt Financing $4.60M -
01 Jul 2017
Seed $3.40M -
01 Jan 2017
Spinout Undisclosed 1
University of Helsinki
01 Jan 2016

Valo Therapeutics Ltd Alternatives & Competitors

View All Alternatives
Valo Therapeutics Ltd vs
NEC OncoImmunity AS
NEC OncoImmunity AS Norway

Empowering cancer immunotherapy with artificial intelligence

Seed
42 employees
AI, Biotechnology
Valo Therapeutics Ltd vs
Memgen, Inc.
Memgen, Inc. United States

Memgen's Vision: Develop Life-Saving Cancer Immunotherapies

Venture round
7 employees
Biotechnology, Health Care
Valo Therapeutics Ltd vs
VacV Biotherapeutics
VacV Biotherapeutics United Kingdom

Developing oncolytic viruses as therapeutics for cancer

Seed
6 employees
Biotechnology, Health Care
View all alternatives

FAQ About Valo Therapeutics Ltd

Reinventing Cancer Immunotherapy
Valo Therapeutics Ltd was founded in 2016.
Valo Therapeutics Ltd is headquartered in Finland.
Valo Therapeutics Ltd operates in Biotechnology, Health Care and Health and Wellness. Its work centres on cancer immunotherapy, oncolytic viruses, viral vectors and therapeutic vaccination. Its customers include Cancer Patients, Healthcare Providers and Medical Researchers.
Valo Therapeutics Ltd has a B2B and B2B2C business model. Its revenue comes from Product Sales and Licensing.
Valo Therapeutics Ltd has approximately 11 employees.
Valo Therapeutics Ltd has completed 6 funding rounds, raising a total of $39.21M.
Valo Therapeutics Ltd offers: Development of Novel Immunotherapies, Cancer Treatment Platforms, Oncolytic and Non-replicating Vector Technologies.
Top alternatives and competitors to Valo Therapeutics Ltd include NEC OncoImmunity AS, Memgen, Inc., VacV Biotherapeutics, DNAtrix, Neon Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Valo Therapeutics Ltd and NEC OncoImmunity AS are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Valo Therapeutics Ltd, https://bouncewatch.com/company/valo-therapeutics, updated 2 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout